Trimetrexate glucuronate

Trimetrexate glucuronate is a chemotherapeutic agent used in the treatment of certain types of cancer. It is a folic acid antagonist that inhibits the enzyme dihydrofolate reductase, which is necessary for the synthesis of DNA and RNA. This inhibition results in the prevention of cell growth and division, leading to the death of rapidly dividing cells such as cancer cells.

Mechanism of Action

Trimetrexate glucuronate works by inhibiting the enzyme dihydrofolate reductase. This enzyme is crucial for the synthesis of tetrahydrofolate, a compound necessary for the production of purine and pyrimidine, which are the building blocks of DNA and RNA. By inhibiting this enzyme, trimetrexate glucuronate prevents the synthesis of these nucleotides, thereby inhibiting cell growth and division.

Clinical Use

Trimetrexate glucuronate is used in the treatment of certain types of cancer, including leukemia, lymphoma, and solid tumors. It is often used in combination with other chemotherapeutic agents to increase its effectiveness.

Side Effects

Like all chemotherapeutic agents, trimetrexate glucuronate can cause a range of side effects. These can include nausea, vomiting, diarrhea, and hair loss. More serious side effects can include bone marrow suppression, leading to a decrease in white blood cells, red blood cells, and platelets.

Pharmacokinetics

Trimetrexate glucuronate is administered intravenously. It is metabolized in the liver and excreted in the urine.

See Also

• Chemotherapy
• Cancer treatment
• Dihydrofolate reductase
• Folic acid